[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tango Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":150},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,92,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100586992","phase-1-study-to-evaluate-the-safety-tolerability--efficacy-of-tng462-in-combination-in-pdac--nsclc-patients-100586992",false,"NCT06922591","Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","A Phase 1\u002F2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation","Inclusion Criteria:\n\n1. Is ≥18 years of age at the time of signature of the main study ICF.\n2. Has an ECOG PS of 0 or 1.\n3. Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene\n4. Arms A and B only: Has a tumor with a RAS mutation\n5. Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC\n6. Has received prior standard therapy\n7. Arms A and B only: Must not have received prior RAS-targeted therapy\n8. Has evidence of measurable disease based on RECIST v1.1.\n9. Adequate organ function\n10. Must be able to swallow tablets.\n11. Negative pregnancy test at screening\n12. Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n1. Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor\n2. Arms A and B only: Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805\n3. Known allergy, hypersensitivity or intolerance to TNG462 (all arms), RMC-6236 Arm A), RMC-9805 (Arm B), mFOLFIRINOX (Arm C), gemcitabine\u002Fnab-paclitaxel (Arm D) or their excipients\n4. Has uncontrolled intercurrent illness that will limit compliance with the study requirements.\n5. Has an active infection requiring systemic therapy.\n6. Is currently participating in or has planned concurrent participation in a study of another investigational agent or device.\n7. Has impairment of GI function or disease that may significantly alter the absorption of the oral medications\n8. Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms\n9. Has current active liver disease from any cause\n10. Is known to be HIV positive, unless all the following criteria are met:\n\n    1. CD4+ count ≥300\u002FµL.\n    2. Undetectable viral load.\n    3. Receiving highly active antiretroviral therapy\n11. Has clinically relevant cardiovascular disease\n12. History of or presence of active interstitial lung disease\n13. Is a female patient who is pregnant or lactating\n14. Is unwilling or unable to comply with the scheduled visits, study treatment administration plan, laboratory tests or other study procedures and study restrictions.\n15. Has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion may affect the safety of the patient or impair the ability to assess study results","ALL","18 Years",{"count":19,"type":20},183,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","TNG462-C102 is a Phase 1\u002F2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine\u002Fnab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.",[27,28,29,30,31,32,33,34],"PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","NSCLC","RAS Mutation","MTAP Deletion","Lung Cancer","Pancreatic Cancer Metastatic","Thoracic Cancer",[36,37,38,39,40,41,42],"PRMT5 inhibitor","RAS G12D","Multi RAS","RMC-9805","RMC-6236","Thoracic","Targeted therapy","RECRUITING","2026-05-12",{"date":46,"type":47},"2026-05-14","ACTUAL",{"date":49,"type":47},"2025-05-31",{"date":51,"type":20},"2027-12",{"name":53,"class":54},"Tango Therapeutics, Inc.","INDUSTRY",18,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":21,"phases":65,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100495563","phase-1-safety-and-tolerability-of-tng462-in-patients-with-mtap-deleted-solid-tumors-100495563","NCT05732831","Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","A Phase 1\u002F2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Age: ≥18 years-of-age at the time of signature of the main study ICF\n2. Performance status: ECOG Performance Score of 0 to 1\n3. Confirmed histologic or cytologic diagnosis of a locally advanced, metastatic, and\u002For unresectable solid tumor\n4. Prior standard therapy, as available\n5. Documented bi-allelic (homozygous) deletion of MTAP in a tumor detected by next- generation sequencing or absence of MTAP protein in a tumor detected by IHC.\n6. Adequate organ function\u002Freserve per local labs\n7. Adequate liver function per local labs\n8. Adequate renal function per local labs\n9. Negative serum pregnancy test result at screening\n10. Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n1. Known allergies, hypersensitivity, or intolerance to TNG462, or its excipients or to pembrolizumab in the combination treatment arms\n2. Uncontrolled intercurrent illness that will limit compliance with the study requirements\n3. Active infection requiring systemic therapy\n4. Currently participating in or has planned participation in a study of another investigational agent or device\n5. Impairment of GI function or disease that may significantly alter the absorption of oral TNG462\n6. Active prior or concurrent malignancy.\n7. Central nervous system metastases associated with progressive neurological symptoms\n8. Current active liver disease from any cause\n9. Known to be HIV positive, unless all of the following criteria are met:\n\n   1. CD4+ count ≥300\u002FμL\n   2. Undetectable viral load\n   3. Receiving highly active antiretroviral therapy\n10. Clinically relevant cardiovascular disease\n11. A female patient who is pregnant or lactating\n12. Patient is unwilling or unable to comply with the scheduled visits, drug administration plan, laboratory tests, biopsy, or other study procedures and study restrictions\n13. Patient has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, may affect the safety of the patient or impair the assessment of study results",{"count":64,"type":20},225,[23,24],"This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.",[68],"Locally Advanced Solid Tumor",[70,71,72,29,73,74,75,76,77,78,79,80,81,82],"MTAP deletion","PRMT5","cholangiocarcinoma","mesothelioma","MPNST","Tango","pancreatic","sarcoma","urothelial","gallbladder","liver","renal","breast","2026-04-17",{"date":85,"type":47},"2026-04-21",{"date":87,"type":47},"2023-05-26",{"date":89,"type":20},"2026-09",{"name":53,"class":54},26,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":110,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100578380","phase-1-safety-and-tolerability-of-tng456-alone-and-in-combination-with-abemaciclib-in-patients-with-solid-tumors-with-mtap-loss-100578380","NCT06810544","Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","A Phase 1\u002F2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","Inclusion Criteria:\n\n* Has a tumor with a confirmed MTAP loss\n* Is ≥18 years of age at the time of signature of the main study ICF\n* Has had progression or an inadequate response to or is intolerant of the approved standard of care therapy, no standard of care therapy exists, or the investigator has determined that treatment with the standard of care therapy is not appropriate.\n* Is able to swallow tablets\n* Adequate Organ function\u002Freserve per local labs\n* Negative serum pregnancy test result at screening\n* Has an ECOG performance status score of 0 to 1\n* Has measurable disease based on RECIST v1.1 or a confirmed glioblastoma (IDH-wildtype) with radiographic evidence of disease progression or recurrence defined by RANO 2.0.\n* Has an ECOG performance score of 0 to 1 or for GBM has a Karnofsky performance status score ≥70.\n\nExclusion Criteria:\n\n* A female patient is who is pregnant or breastfeeding\n* Has impaired GI function or disease that may significantly alter the absorption of oral study treatment(s)\n* Has an active infection requiring systemic therapy\n* Has received prior treatment with a PRMT5 inhibitor or a MAT2A inhibitor\n* Patients in the expansion receiving the combination therapy that have received prior treatment with a CDK4\u002F6 inhibitor\n* Clinically relevant cardiovascular disease\n* Has a prior or ongoing clinically significant illness may affect the safety of the patient, impair the assessment of study results or compliance with the protocol",{"count":100,"type":20},191,[23,24],"This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.",[104,105,106,107,108,32,109],"Non Small Cell Lung Cancer","Glioma Glioblastoma Multiforme","Glioma, Malignant","Solid Tumor","Non-Small Cell Adenocarcinoma","Brain Tumor",[111,36,112,113,75],"MTAP","CDK 4\u002F6","abemaciclib","2026-04-10",{"date":116,"type":47},"2026-04-13",{"date":118,"type":47},"2025-03-24",{"date":120,"type":20},"2027-09-30",{"name":53,"class":54},15,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},"100507446","phase-1-study-of-tng260-and-an-anti-pd-antibody-in-stk11-mutated-solid-tumors-100507446","NCT05887492","Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","A Phase 1\u002F2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors","Inclusion Criteria:\n\n* Is ≥18 years of age at the time of signature of the main study ICF.\n* Has ECOG performance status of 0 or 1.\n* Has measurable disease based on RECIST v1.1.\n* All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytical method\n* Has confirmed histologic or cytologic diagnosis of a locally advanced or metastatic solid tumor.\n* Adequate organ function\u002Freserve per local labs\n* Adequate liver function per local labs\n* Adequate renal function per local labs\n* Negative serum pregnancy test result at screening\n* Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n* Known allergies, hypersensitivity, or intolerance to TNG260, PD-1 antibody or its excipients\n* Uncontrolled intercurrent illness that will limit compliance with the study requirements\n* Active infection requiring systemic therapy\n* Currently participating in or has planned participation in a study of another investigational agent or device\n* Impairment of GI function or disease that may significantly alter the absorption of oral TNG260\n* Active prior or concurrent malignancy.\n* Central nervous system metastases associated with progressive neurological symptoms\n* Current active liver disease from any cause\n* Clinically relevant cardiovascular disease\n* A female patient who is pregnant or lactating",{"count":131,"type":20},126,[23,24],"The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.\n\nThe main question\\[s\\] it aims to answer are:\n\n* the recommended dose for Phase 2\n* to evaluate the safety and tolerability of the combination therapy\n* to determine the pharmacokinetics of TNG260\n* to evaluate the initial antineoplastic activity\n\nParticipants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.",[104,135,32,136],"Solid Tumors, Adult","Lung Adenocarcinoma",[138,139,140],"STK11","KRAS wild type","LKB1","2025-11-14",{"date":143,"type":47},"2025-11-18",{"date":145,"type":47},"2023-06-12",{"date":147,"type":20},"2026-06",{"name":53,"class":54},13,""]